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Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease
caused by the fungus Aspergillus fumigatus, and is a leading cause of
invasive fungal infection-related mortality and morbidity in patients
with hematological malignancies and bone marrow transplants. We
developed and tested a novel probe for noninvasive detection of
A. fumigatus lung infection based on antibody-guided positron emis-
sion tomography and magnetic resonance (immunoPET/MR) imaging.
Administration of a [64Cu]DOTA-labeledA. fumigatus-specific monoclo-
nal antibody (mAb), JF5, to neutrophil-depleted A. fumigatus-infected
mice allowed specific localization of lung infection when combined
with PET. Optical imaging with a fluorochrome-labeled version of
the mAb showed colocalization with invasive hyphae. The mAb-
based newly developed PET tracer [64Cu]DOTA-JF5 distinguished
IPA from bacterial lung infections and, in contrast to [18F]FDG-PET,
discriminated IPA from a general increase in metabolic activity as-
sociated with lung inflammation. To our knowledge, this is the first
time that antibody-guided in vivo imaging has been used for non-
invasive diagnosis of a fungal lung disease (IPA) of humans, an
approach with enormous potential for diagnosis of infectious dis-
eases and with potential for clinical translation.
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Despite the success of therapeutics fighting against especiallybacteria and fungi, infectious diseases still remain one of the
main causes of death worldwide (1). Beside effective therapeu-
tics, the early and reliable differential diagnosis of infectious
diseases is of utmost importance; here noninvasive imaging can
have a huge impact. Imaging of infectious diseases is an emerging
field still in its infancy, but is nevertheless attracting considerable
attention from many disciplines in biomedical research, as well as
in patient care. There are several challenging aspects of imaging
infectious diseases, not at least the clear and reliable differentia-
tion between bacterial, fungal, and viral infection needed for the
best treatment options. Furthermore, infection is typically linked
to inflammation, which makes it mandatory to use pathogen
specific imaging probes to definitively and rapidly diagnose the
causative agent of the infectious disease.
Invasive pulmonary aspergillosis (IPA) is a frequently fatal lung
disease of neutropenic patients caused by the ubiquitous airborne
fungus Aspergillus fumigatus. As a leading cause of death in he-
matological malignancy and hematopoietic stem cell transplant
patients, the fungus accounts for the majority of the >200,000 life-
threatening infections annually with an associated mortality rate of
30–90% (2). Diagnosis of IPA is a major challenge as clinical
manifestations of the disease (febrile episodes unresponsive to
antibiotics, pulmonary infiltrates and radiological abnormalities)
are nonspecific, and methods for the detection of circulating
biomarkers such as β-D-glucan or galactomannan (GM) in the
bloodstream lack specificity or sensitivity (3). For this reason,
culture of the fungus from lung biopsy tissues remains the gold
standard test for IPA diagnosis (4), but this invasive procedure
lacks sensitivity, delays diagnosis, and is frequently not possible in
neutropenic patients. Recently, detection of A. fumigatus GM or
mannoprotein antigens in bronchoalveolar lavage (BAL) has
shown enormous promise for the early detection of the disease
especially when combined with point-of-care diagnostics (5).
However, BAL recovery is similarly intrusive and so a sensitive,
specific, and minimally invasive test that is amenable to repeated
application is needed to allow diagnostic-driven treatment with
antifungal drugs. Such a test should be able to discriminate be-
tween active lung infection caused by hyphal proliferation of the
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fungus and inactive spores that are a common component of in-
haled air. Conventional imaging modalities such as computed
tomography (CT) and magnetic resonance imaging (MRI) are
able to produce high contrast images of all structures within the
human body but they are not able to distinguish between invasive
fungal infections and those caused by other microorganisms, or to
discriminate these from cancer tissues (6, 7). Molecular imaging
using positron emission tomography (PET) is able to define the
metabolic properties of living cells as well as their molecular
structures when suitable radiolabeled tracers are used (8). Here,
we use a radiolabeled monoclonal antibody (mAb) specific to the
active growth phase of A. fumigatus to diagnose IPA in a neu-
tropenic animal model of the disease with PET/MRI. Our work
shows that antibody-based immunoPET can be used successfully
to noninvasively identify this challenging lung disease.
Results
We hypothesized that target-specific radiolabeled antibodies
and immunoPET imaging could be used noninvasively and
in vivo to detect lung infections caused by A. fumigatus. We used
A. fumigatus-infected, neutrophil-depleted mice as a model of
IPA to mimic the suppressed innate immunity of patients at
high-risk for IPA, and chose an abundant hyphal-associated
antigen as the in vivo target for immunoPET/MR imaging using
the well characterized A. fumigatus-specific mAb JF5. The JF5
antibody binds to an extracellular mannoprotein antigen se-
creted during active growth of the pathogen only, and it is used in
a point-of-care lateral-flow assay for detection of diagnostic an-
tigen in human serum and BAL samples (5).
To test the immunoreactivity and the serum stability of the
chelator and fluorochrome labeled mAb JF5 after modification in
vitro tests were performed. Immunoreactivity of mAb JF5 fol-
lowing labeling with the chelator DOTA and the fluorochrome
DyLight 650 was investigated by immunofluorescence using ger-
minated spores of A. fumigatus. Labeling of the antibody with the
chelator or the fluorochrome did not alter the hyphal-specific
binding of the antibody to its target mannoprotein antigen (Fig.
S1A). Intense fluorescence of hyphae but lack of staining of un-
germinated spores of the fungus was observed in each case, con-
sistent with binding of the antibody to the active growth phase of
the pathogen. Similarly, there was no significant loss of antibody
immunoreactivity in ELISA tests using a saturating concentration
of purified mannoprotein antigen (Fig. S1B), further demon-
strating that labeling of the JF5 antibody with the chelator DOTA
or fluorochrome DyLight 650 had no significant effect on binding
of the antibody to its target antigen. For assessment of the serum
stability, one volume of [64Cu]DOTA-JF5 in its final formulation
was incubated with three volumes of C57BL/6 serum at 37 °C for
various time points and immediately analyzed by Radio-HPSEC.
The analysis showed no signs of proteolytic degradation, protein
aggregation or copper transchelation to serum proteins over the
time of 48 h under these conditions (Fig. S1 C–F).
JF5 Antibody Binds to A. fumigatus in Vivo. To test the suitability of
JF5 as an intravital whole body diagnostic tool when equipped
with a suitable label, we investigated first whether fluorochrome-
labeled JF5 was able to detect A. fumigatus in infected lungs of
experimental animals. Neutrophil-depleted mice were intra-
tracheally (i.t.) infected with conidia of a genetically modified
strain of the fungus expressing the fluorescent protein tdTomato
(A. fumigatustdTomato; Fig. 1A) and, 48 h later, the lungs were
excised and the presence of fungal masses was confirmed in se-
rial sections by methenamine silver staining (Fig. 1B). Consec-
utive sections were then probed with fluorochrome-labeled JF5
or the respective fluorochrome-labeled isotype control. Here,
JF5 gave an intense staining of fungal elements (Fig. 1C) that
produced a cell-wall selective pattern, whereas isotype controls
were negative (Fig. 1C). In a second set of experiments the la-
beled JF5 antibody was injected 24 h after infection into the
circulation of mice (Fig. 1D). Lung lobes were dissected 24 h
later and were analyzed by confocal microscopy. Large red fluo-
rescent fungal masses were detected (green), which were cola-
beled with fluorescent JF5 (red) on individual hyphae, as well as
extracellular antigen in close proximity to hyphal elements
(Fig. 1E). Mice injected with the fluorescent isotype control
showed the fluorescent fungal elements only without an isotype-
derived second fluorescent signal (Fig. 1E). These experiments
show that JF5 specifically binds to the target mannoprotein an-
tigen in A. fumigatus-infected lungs in vivo and therefore qual-
ifies as a potential diagnostic agent for whole-body molecular
imaging using PET/MRI.
[64Cu]DOTA-JF5 Specifically Detects A. fumigatus Infection in Vivo.
For immunoPET imaging, JF5 was conjugated with the chelator
DOTA and then labeled with the radionuclide 64Cu, which allows
consecutive imaging for up to 3 d. Neutropenic mice infected with
A. fumigatus were injected with [64Cu]DOTA-JF5 and the distri-
bution of the tracer was evaluated by PET following MRI at 3, 24,
and 48 h after infection (Fig. 2 and Fig. S2). To evaluate the
specificity of [64Cu]DOTA-JF5, biodistribution studies with sev-
eral control infection models were performed. Animals were i.t.
infected with A. fumigatus or the bacterial pathogen Strepto-
coccus pneumoniae, or systemically with the bacterial patho-
gen Yersinia enterocolitica, and the in vivo biodistribution of
[64Cu]DOTA-JF5 was assessed 3, 24, and 48 h later by PET/
MRI (Fig. 2 and Fig. S2). PET images revealed a significantly
elevated uptake of [64Cu]DOTA-JF5 in the lungs of A. fumi-
gatus-infected animals compared with lungs of PBS-treated
control mice or mice infected with S. pneumoniae or Y. enterocolitica
(Fig. 2A). The PET signal colocalized with the fungal lesions ob-
served in the MR images. The mean [64Cu]DOTA-JF5 uptake 48 h
postinfection (hpi) in the lungs of the imaged mice was lowest in
Y. enterocolitica-infected animals with 4.4 ± 0.3%ID/cc, followed by
S. pneumoniae-infected and PBS-treated mice (5.2 ± 0.2; 5.9 ±
0.6%ID/cc). Compared with these controls, tracer uptake was sig-
nificantly higher in the lungs of A. fumigatus-infected mice (11.9 ±
1.3%ID/cc) (Fig. 2B). The ex vivo biodistribution 48 hpi showed a
significantly elevated uptake of [64Cu]DOTA-JF5 with 34.6 ±
7.4%ID/g in A. fumigatus-infected lung tissue compared with the
lungs of PBS controls (7.7 ± 2.0%ID/g), S. pneumoniae (8.1 ±
0.6%ID/g) and Y. enterocolitica (8.1 ± 1.5%ID/g) infected mice
(Fig. 2C). A significant higher uptake of the tracer was already
detectable 24 h after infection (Fig. S1). The discrepancy of ap-
proximately a factor of 2 in absolute quantification between%ID/g of
post mortem biodistibution and in vivo small animal PET (%ID/cc)
data are caused mainly by 511-keV photon attenuation in the
animal and partial volume effects. However, the ratios of lungs
and muscle tissue between the tested groups were similar in the in
vivo PET quantification and the ex vivo gamma-counting (9).
Besides increased signal intensity in the lung, we also found ele-
vated signals in the blood, liver, spleen, and kidney. However, the
analysis of fungal presence in these compartments using colony-
forming unit (CFU) measurements revealed none to very limited
colonization with the pathogen 48 h after infection (Fig. S3).
To further confirm the specificity of the [64Cu]DOTA-JF5 tracer,
blocking experiments were performed. Here, 1 mg of mannoprotein-
specific IgM mAb ND12 or 1 mg of nonradiolabeled JF5 mAb
were injected into infected animals 3 h before the injection
of [64Cu]DOTA-JF5 (Fig. 3A). In addition, the isotype control
antibody MG3-35 was radiolabeled and injected in A. fumigatus-
infected mice. The PET images showed the highest signal intensity in
the lungs of A. fumigatus-infected nonblocked mice and decreased
intensities in the relevant blocking controls (Fig. 3A), which was
confirmed by ex vivo autoradiography of the lungs (Fig. 3A, Lower).
The quantification of the data retrieved from the PET images
48 hpi (Fig. 3B) showed a reduced uptake from 10.2 ± 1.3%ID/cc
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in the lungs of A. fumigatus-infected nonblocked animals down to
8.8 ± 2.2%ID/cc in the lungs of mice which received 1 mg of the
blocking antibody JF5, 7.7 ± 2.0%ID/cc in the lungs of mice
blocked with 1 mg ND12 and 8.0 ± 1.7%ID/cc in mice imaged
with the radiolabeled isotype control mAb MG3-35. PBS-
treated noninfected mice had significantly lower [64Cu]DOTA-
JF5 uptake in the lungs (6.0 ± 1.0%ID/cc) compared with the
A. fumigatus-infected mice (Fig. 3B). Similar results were al-
ready evident at 24 hpi (Fig. S4).
Ex vivo biodistribution 48 hpi showed a significantly higher
uptake of [64Cu]DOTA-JF5 with 29.8 ± 7.4%ID/g in lung tissue
of infected mice compared with PBS controls (9.0 ± 2.3%ID/g).
A lower uptake was observed with the radiolabeled isotype
control antibody MG3-35 (21.8 ± 0.7%ID/g). Also the blocking
with 1mg ND12 (22.1 ± 3.3%ID/g) or JF5 (22.6 ± 8.1%ID/g)
resulted in lower uptake of the tracer [64Cu]DOTA-JF5 in in-
fected lung tissue compared with the mice imaged solely with
[64Cu]DOTA-JF5 (positive control; Fig. 3C). Furthermore, the
in vivo imaging results were confirmed by the ex vivo autoradi-
ography where a high tracer uptake was seen in the lungs of the
A. fumigatus-infected animals and a lower uptake was seen in
the controls. The focal lesions of the fungus in the lungs of the
A. fumigatus-infected animals perfectly matched with the accu-
mulated radioactivity as revealed with the autoradiography.
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Fig. 1. Binding specificity of JF5 to A. fumigatus in infected mouse lungs. (A) Experimental workflow for the in situ binding of the mAb JF5: (1) Neutrophil
depletion by i.p. injection of 100 μg anti-Gr-1 antibody (clone RB6-8C5) 17 h before infection. (2) Intratracheal infection with A. fumigatustdTomato. (3) After 48 h,
lung explantation, fixation, and slicing followed by in situ staining with either JF5-DyLight650 or methenamine silver. (B) A. fumigatus-infected lung lobe
section stained with methenamine silver. Fungal biomass can be detected by its black appearance (yellow arrowheads). (C) Tissue sections of A. fumiga-
tustdTomato (green) infected lungs stained with JF5-DyLight650 (displayed in false color red) or mouse IgG3 isotype control (red). White arrowheads indicate
expression of tdTomato in the cytoplasm and JF5-antigen in the hyphal cell wall. (D) Experimental workflow for JF5 binding in vivo: (1) Neutrophil depletion
by i.p. injection of 100 μg of anti-Gr-1 antibody (clone RB6-8C5) 17 h before infection. (2) Intratracheal infection with A. fumigatustdTomato. (3) i.v. injection of
JF5-DyLight650 or fluorochrome-labeled mouse IgG3 isotype control 24 h after fungal infection. (4) Another 24 h later, lung explantation, followed by (5) in
situ confocal microscopy of longitudinally sectioned lung. (E) Micrographs of A. fumigatustdTomato (green) infected lungs treated with JF5-DyLight650 (red) or
mouse IgG3 isotype control (red). Blue boxes indicate regions of interest, which are shown at higher magnification in the insets. White arrowheads indicate
expression of tdTomato in the cytoplasm and white arrows indicate expression of JF5-antigen in the hyphal cell wall, respectively.
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Examples of the autoradiography and the corresponding H&E
staining are depicted in Fig. 3A, Lower.
[18F]FDG Does Not Allow Identification of A. fumigatus Infection.
The clinical standard for PET-based diagnosis in oncology is
[18F]FDG-PET. To study whether this tracer was able to dis-
criminate between inflammatory processes and infections caused
by fungal and bacterial pathogens, we performed [18F]FDG-PET
in animals infected with A. fumigatus and S. pneumoniae.
[18F]FDG-PET-imaging showed strong lung uptake of the tracer,
irrespective of whether animals were infected with A. fumigatus
or S. pneumoniae. Even animals that only received an i.t. ad-
ministration of sterile PBS showed a clear uptake of [18F]FDG
24 and 48 h after treatment (Fig. 4A). The %ID/cc in the lungs of
A. fumigatus-infected animals between 3 and 48 h after infection
rose from 4.7 ± 1.6 to 12.3 ± 1.8, whereas the %ID/cc in the
lungs of the PBS-treated control animals increased from 3.1 ±
0.4 to 11.7 ± 3.1 (Fig. 4B). Likewise an increasing [18F]FDG
uptake was observed in the S. pneumoniae infected cohort with
3.4 ± 0.5%ID/cc (3 h) to 13.3 ± 4.6%ID/cc (48 h; Fig. 4B). The
ex vivo biodistribution further confirmed the in vivo PET
quantification, also showing no significant differences in the
[18F]FDG uptake of the various groups (Fig. 4C). These data
demonstrated that the metabolism-sensitive tracer [18F]FDG
lacks specificity and thus is unable to distinguish between in-
flammation, sterile irritation and pathogen-induced infection
and is incapable of identifying etiological agents of infection.
Discussion
IPA is a leading cause of death in immunocompromised patients
caused by the ubiquitous fungus A. fumigatus (2). The high rates
of morbidity and mortality associated with this disease are due,
to a large extent, to the paucity of diagnostic tests that allow
accurate and rapid diagnosis followed by early treatment with
mold-active drugs in patients presenting with fever of unknown
origin (3). Currently, IPA is diagnosed based on clinical symp-
toms, radiology, and laboratory tests such as mycological culture,
PCR, GM antigen tests, and microscopy (4, 10). However, most
of these methods are unspecific and time consuming, impeding
an early and accurate diagnosis. Radiology enables noninvasive
identification of lung abnormalities, but technologies such as
high-resolution CT, though able to visualize lung infections, are
considered nonspecific and so are unable to discriminate be-
tween different fungal pathogens or to differentiate fungal
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Fig. 2. [64Cu]DOTA-JF5 as disease-specific PET-tracer for A. fumigatus lung infection. (A) Sagittal maximum intensity projections (MIP), MRI, and fused PET/MRI
images of PBS-treated mice and S. pneumoniae-, Y. enterocolitica-, and A. fumigatus-infected mice injected with [64Cu]DOTA-JF5 (48 h after infection). Tracer
injection demonstrates highly specific accumulation in A. fumigatus-infected lung tissue compared with bacterial-infected or sham-treated animals. (A, Lower) Lungs
of the respective animals. (B) Quantification of the in vivo PET images showed a significantly higher uptake of [64Cu]DOTA-JF5 in the lungs of A. fumigatus-infected
animals compared with the lungs of the control groups. (C) The ex vivo biodistribution confirmed the in vivo PET results with significantly higher uptake of
[64Cu]DOTA-JF5 in the lungs of A. fumigatus-infected animals compared with the lungs of control animals 48 hpi. The systemic infection at the late stage of the
disease in neutropenic and A. fumigatus-infected animals is reflected by higher tracer accumulation in lymphatic and other organs. Black bars, PBS-treated controls
(n = 8); blue bars, S. pneumoniae-infected mice (n = 5); orange bars, Y. enterocolitica-infected mice (n = 5); red bars, A. fumigatus-infected mice (n = 5). Data are
expressed as the average ± SD (%ID/cc: PET; %ID/g: ex vivo biodistribution), one-way ANOVA, post hoc Tukey–Kramer corrected for multiple comparisons, *P < 0.05.
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infections from other infectious etiologies. PET/MRI has proven
to be a very powerful tool for diagnosis of cancer (11), but its use
in infection diagnosis has so far been limited (6).
Existing tracers for PET imaging are not able to distinguish
between malignancies and sterile or pathogen-induced inflam-
mations (12, 13). Furthermore, it is even more challenging to
correctly diagnose the cause of infection because the symptoms
can manifest as nonpathogen-induced diseases such as malignan-
cies (14–16). Although it has been reported that [18F]FDG might
serve as a useful imaging tool for initial diagnosis and therapy
monitoring of IPA (16), our investigations have shown that
increased [18F]FDG uptake in A. fumigatus-infected lungs is in-
distinguishable from the uptake seen during inflammatory reac-
tions due to sterile triggers or other pathogens. Recently,A. fumigatus
detection based on single-photon emission tomography with 99mTc-
labeled morpholino-oligonucleotides specific for fungal 28S rRNA
has been investigated (17). Although A. fumigatus lung infections
are clearly discerned by using this technique, further investiga-
tions in other infectious models are needed to confirm the
specificity of the probe.
PET-based imaging has seen enormous success in oncology
(18–21), but has yet to be fully exploited for infection imaging
(22, 23). Especially in the field of preclinical imaging, an in-
creasing number of biologicals including small molecules, an-
tibodies, their fragments and peptides have been developed and
evaluated for imaging infectious diseases (24–28). Recently,
attempts have been made to visualize IPA in A. fumigatus-infected
animals with microPET/CT using 68Ga radiolabeled siderophores
(29, 30). These small high-affinity chelating compounds are pro-
duced by fungi and bacteria to scavenge iron from the host, and by
Gram-negative bacterial pathogens as virulence factors (31). Al-
though rapid uptake of 68Ga by the A. fumigatus siderophore
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Fig. 3. JF5 binding is specific for A. fumigatus. (A) Sagittal MIP, MRI, and PET/MRI images of PBS-treated and A. fumigatus-infected mice. To test the
specificity of the newly developed tracer, A. fumigatus-infected animals were either injected with a radiolabeled isotype control antibody (clone MG 3–35) or
blocking experiments were performed. For blocking A. fumigatus-infected animals received 1 mg of nonradiolabeled ND12 or JF5 antibody 3 h prior the
injection of the [64Cu]DOTA-JF5. Tracer biodistribution demonstrates in PET images as high accumulation in A. fumigatus-infected lung tissue 48 hpi com-
pared with PBS-treated, isotype control imaged or blocked lungs of the infected animals. (A,Middle) Lungs of the respective animals. (A, Bottom) The ex vivo
autoradiography and the corresponding H&E staining of the slides show the strong accumulation of the tracer [64Cu]DOTA-JF5 in the lungs of the infected
animals in contrast to the controls. (B) Quantification of the in vivo PET images showed a higher uptake of [64Cu]DOTA-JF5 in the lungs of A. fumigatus-
infected animals compared with the lungs of the PBS controls, imaging with the radiolabeled MG 3–35 (isotype control) and the blocking experiments. (C) The
ex vivo biodistribution confirmed the in vivo PET results with significantly higher uptake of [64Cu]DOTA-JF5 in the lungs of A. fumigatus-infected animals
compared with the lungs of PBS control animals. Black bars, PBS-treated controls; green bars, A. fumigatus-infected mice imaged with the radiolabeled
isotype control antibody MG3-35 (n = 5); purple bars, A. fumigatus-infected mice blocked with 1 mg of IgM ND12 antibody (n = 5), blue bars, A. fumigatus-
infected mice blocked with 1 mg of nonradiolabeled JF5 antibody (n = 10); red bars, A. fumigatus-infected mice (n = 9). Data are expressed as the average ±
SD (%ID/cc: PET; %ID/g: ex vivo biodistribution), one-way ANOVA, post hoc Tukey–Kramer corrected for multiple comparisons, *P < 0.05.
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TAFC has been shown to occur under conditions of iron de-
pletion, patients who acquire fungal infections typically suffer
from iron overload thereby potentially reducing tracer uptake
and sensitivity of this method. Furthermore, TAFC-mediated 68Ga
uptake has also been demonstrated in Fusarium solani and Rhizopus
oryzae, invasive fungal pathogens that, like Aspergillus, cause dissem-
inated infections in immunocompromised patients known as
fusariosis and mucormycosis, respectively (32).
ImmunoPET has recently been used for tracking simian im-
munodeficiency virus (SIV) infection in macaques (33), and our
work is, to our knowledge, the first example of its exploitation in
the rapid and specific detection of a lethal fungal infection. Due
to the long in vivo half-life of [64Cu]DOTA-JF5 demonstrated
here, we have shown that this immunoPET tracer would be an
ideal candidate for repeated imaging of patients following a
single injection of the radioactive tracer. Significantly, the JF5
Min
Max
PBS control S. pneumoniae A. fumigatus
3 
h 
p.
i.
A
     MIP        MRI      Fusion      MIP        MRI      Fusion      MIP        MRI      Fusion 
B
PBS control S. pneumoniae A. fumigatus
24
 h
 p
.i.
48
 h
 p
.i.
3 h p.i.
%
ID
/c
c 
lu
ng
*
24 h p.i. 48 h p.i.
0
5
10
15
20
Blood
%
ID
/g
Heart Lung Liver Spleen ColonStomach Kidney r Kidney l Muscle Brain
0
10
20
30
100
300
200
*
*
* *
* *
*
*
ex vivo biodistributionC
[18F]FDG
Fig. 4. [18F]FDG does not allow identification of A. fumigatus infection. (A) Sagittal MIP, MRI, and PET/MRI images of PBS-treated-, S. pneumoniae-, and
A. fumigatus-infected mice imaged with [18F]FDG (3, 24, and 48 h after infection). All animals, including the PBS-treated mice, presented a highly elevated
uptake of [18F]FDG within the lungs 24 and 48 h after the infection with A. fumigatus or S. pneumoniae. (B) Quantification of the in vivo PET images showed
no significant differences in the uptake of [18F]FDG in the lungs of A. fumigatus-infected animals compared with the lungs of the control groups 24 and 48 h
after infection. (C) The ex vivo biodistribution confirmed the in vivo [18F]FDG-PET results with no significant differences in the uptake of the lungs of A.
fumigatus-infected animals compared with the lungs of control animals 48 hpi. Black bars, PBS-treated controls (n = 10); blue bars, S. pneumoniae-infected
mice (n = 5); red bars, A. fumigatus-infected mice (n = 5). Data are expressed as the average ± SD (%ID/cc: PET; %ID/g: ex vivo biodistribution), one-way
ANOVA, post hoc Tukey–Kramer corrected for multiple comparisons, *P < 0.05.
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antibody binds to a mannoprotein antigen released during active
growth of the fungus only (34), and so is able to discriminate
between infective hyphae and inactive spores, an important
consideration given the abundance of Aspergillus spores in
inhaled air. The hyphal-specific nature of our immunoPET
tracer may therefore prove useful in monitoring infection
in response to antifungal treatment. In the biodistribution
analyses of infected animals, we found increased radioactive
signals also in organs other than the infected lung. Signal
enrichment in the liver might be due to nonspecific hepatic
clearance of the radiolabeled antibody as seen by others (35),
whereas nonspecific enrichment of radiolabeled antibody in
kidney, blood, and spleen tissues has been reported in other
immunoPET studies (33). Furthermore, in animals with IPA,
it is likely that extracellular JF5 mannoprotein antigen re-
leased from infectious foci in the lungs accumulates in organs
following shedding and circulation in the bloodstream, be-
cause the antigen is readily detectable in the serum of neu-
tropenic animals and humans suffering from IPA (34, 36, 37).
The methodology is essentially translatable to humans because the
JF5 antibody detects a signature molecule of A. fumigatus infection
that is clinically validated for IPA diagnosis in neutropenic pa-
tients using bronchoalveolar lavage fluids and point-of-care di-
agnostics (38). To this end, the antibody has been fully humanized
to enable its use in human disease detection. A humanized version
of the tracer would allow noninvasive identification of IPA in
immunocompromised patients and monitoring of responsiveness
to antifungal treatment.
Materials and Methods
Additional and detailed information are provided in SI Materials andMethods.
All animal experiments were performed according to the German Animal
Protection Law with permission from the Regierungspräsidium Tübingen
and Magdeburg, Landesamt für Natur, Umwelt und Verbraucherschutz Nord-
rhein-Westfalen, and the Niedersächsische Landesamt für Verbraucherschutz und
Lebensmittelsicherheit Braunschweig/Oldenburg, Germany. Neutropenic C57BL/6
OlaHsd mice were i.t. infected with a freshly prepared A. fumigatus spore sus-
pension (4 × 106 per mL). Animals of the control groups were i.t. infected with
1 × 106 CFUs of S. pneumoniae bacteria, i.v. injected with 5 × 104 CFUs of
Y. enterocolitica bacteria or i.t. inoculated with 100 μL of PBS, respectively.
Successful infection was confirmed by CFU assays, where the bacterial and fungal
load of various organs was assessed 24 and 48 h after the respective infection.
[18F]FDG (10–11 MBq) was i.v injected into A. fumigatus- or S. pneumo-
niae-infected animals, and the respective control animals and PET and MR
images were acquired 3, 24, and 48 h after the initial infection by using a
small animal PET scanner (Inveon, Siemens Preclinical Solutions) and a 7 T
small animal MR tomograph (Clinscan, Bruker Biospin MRI). PET images were
normalized to each other, subsequently fused to the respective MR images,
and analyzed by using Inveon Research Workplace software (Siemens
Preclinical Solutions).
To generate the A. fumigatus-specific PET tracer [64Cu]DOTA-JF5, the JF5-
secreting A. fumigatus-specific IgG3 mAb hybridoma cell line, which was
characterized previously (34), was used. JF5 was purified with a HiTrap
Protein G HP column (GE Healthcare Life Sciences), chelator conjugated with
10 mg/mL DOTA-NHS (Chematech), and subsequently radiolabeled with 64Cu
which was created by proton irradiation of enriched 64Ni metal (35-75 mg;
Isoflex, >95% enrichment) electroplated on a silver disk via the 64Ni(p,n)64Cu
nuclear reaction (39). A. fumigatus-, S. pneumoniae-, or Y. enterocolitica-
infected animals and the respective control mice were consecutively imaged
in PET and MRI 3, 24, and 48 h after the infection and i.v. injection of
[64Cu]DOTA-JF5. To assess the specificity of the newly developed PET tracer,
blocking studies were performed. 1 mg of purified Aspergillusmannoprotein-
specific IgM mAb ND12 or 1 mg of purified nonradiolabeled JF5 antibody
were i.v. injected into A. fumigatus-infected animals 3 h before the injection
of the radiolabeled JF5. Static 10-min PET scans were performed 3, 24, and
48 h after application of the tracer. Additionally, an unspecific IgG3 isotype
control antibody (MG3-35, Biolegend) was radiolabeled as described pre-
viously and i.v. injected into A. fumigatus-infected animals.
After the final PET scan, an ex vivo biodistribution of various organs was
performed in the γ-counter (Wallac 1480 WIZARD 3” Gamma Counter; Per-
kin-Elmer) and an ex vivo autoradiography with subsequent H&E staining of
the tissue slices was accomplished.
For application in fluorescence microscopy, purified JF5 mAb was coupled
to DyLight 650 (Thermo Fisher Scientific) and A. fumigatus-infected lung
slices were in situ stained with the fluorescently labeled JF5 or with the
fluorescently labeled IgG3 isotype control MG3-35. For in vivo staining,
A. fumigatus-infected mice were i.v. injected with the fluorochrome-labeled
JF5 or the unspecific isotype control and lungs were explanted 48 h after the
infection for microscopy.
Statistical significance was determined by using a two-tailed t test. For
experiments with more than two investigated groups, statistical signifi-
cances were calculated by using one-way analysis of variance (ANOVA)
followed by Tukey’s Multiple Comparison Test conducted with Origin 8
software (OriginLab).
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